Objectives: Optimal dosing for nebulized colistin methanesulfonate (CMS), the prodrug of colistin, is unknown. We describe the pulmonary and systemic pharmacokinetics of CMS and colistin following nebulization of 0.5 million IU (MIU) of CMS in ventilated patients.
Introduction
Ventilator-associated pneumonia (VAP) is the most common complication due to prolonged mechanical ventilation. In ICUs, VAP represents nearly half of all healthcare-associated infections, affecting 18% of ventilated patients on average. 1, 2 Responsible for a high mortality, ranging from 24% to 50% according to the pathogens involved, VAP prognosis is linked to the efficacy of initial antimicrobial treatment. 3 Gram-negative bacteria (including Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae) are pathogens commonly responsible for VAP. In recent decades, bacterial resistance, particularly in Gram-negative bacilli (GNB), has increased, while at the same time the development of new antibiotics has been limited. 4 In the absence of new antibiotics, colistin appears to be a salvage therapy for multiresistant GNB-induced VAP. 5 Colistin is an old antibiotic of the polymyxin family. Usually administered as an inactive prodrug, colistin methanesulfonate (CMS), colistin is bactericidal against most GNB by acting on their outer membrane. 6, 7 Developed in the 1950s, it was quickly abandoned because of toxicity. In the last decade, better knowledge of its pharmacokinetics properties has allowed safer use and colistin has proved to be less toxic than the aminoglycosides. 8, 9 Until recently, acquired resistance to colistin was uncommon. But with the renewed interest in colistin use, descriptions of cases of acquired resistance are increasing. 10 One of the possible explanations is the difficulty in reaching target concentrations with the usual doses of CMS. Thus, colistin is commonly used by inhalation in cystic fibrosis patients. Its efficacy has been proven for decades in the treatment of infections or colonization with MDR GNB. 12 In critically ill patients, notwithstanding the paucity of evidence, aerosolized colistin in association with parenteral antibiotics (colistin or another) improved outcome of patients with VAP. 13 A previous study in critically ill patients with VAP showed that aerosol delivery of 2 million IU (MIU) of CMS led to very high concentrations of colistin in the epithelial lining fluid (ELF) (9.53-1137 mg/L).
14 Based on these findings, we assumed that aerosol delivery of 0.5 MIU of CMS would be enough to achieve sufficient intrapulmonary colistin concentrations.
The main aim of this study was to assess pulmonary and systemic concentrations of CMS and colistin following nebulization of 0.5 MIU of CMS in critically ill patients with VAP.
Materials and methods

Study population
The study was conducted between July 2014 and April 2015 in 12 adult patients hospitalized in the surgical ICU of the University Hospital of Poitiers, France, who had developed VAP caused by GNB. Patients were eligible if they were between 18 and 85 years of age and developed VAP caused by GNB susceptible to colistin. Patients were excluded if they had received colistin at any time during the 7 days preceding the study, had CL CR ,30 mL/min, or had a personal or family history of myasthenia.
At study onset, the following data were collected: age, sex, weight, height, diagnosis on admission, serum urea, serum creatinine, simplified acute physiology score II (SAPS II) 15 and SOFA score. 16 CL CR was calculated according to the Modification of Diet in Renal Disease (MDRD) formula. 17 
Ethics
The study protocol was approved by the local ethics committee (Comité de Protection des Personnes Ouest III, approval number 2009009578-28) and registered at ClinicalTrials.gov (NCT01060891). Written informed consent was obtained for all patients from their nearest relatives prior to initiation of the study.
CMS administration
Patients received 0.5 MIU of CMS (Colimycine V R , Sanofi, Paris, France) dissolved in 5 mL of saline solution by nebulization over 30 min using a vibrating-mesh nebulizer (Aeroneb Pro V R , Aerogen, Galway, France) every 8 h. Solutions for nebulization were freshly prepared.
During aerosol delivery, all patients were sedated and received volumecontrolled mechanical ventilation with a tidal volume of 7-8 mL/kg of predicted body weight and respiratory rates of 12-15 cycles/min. The humidifier was removed and the nebulizer was inserted near the T-piece connector on the inspiratory arm.
Sampling procedures Blood samples
Blood samples were collected immediately before and 0.5, 1, 2, 3, 5 and 8 h after the beginning of the first nebulization of CMS. They were immediately centrifuged at the bedside (3000 g for 10 min at 4 C) and the plasma was stored at #80 C until analysis.
Bronchoalveolar lavage (BAL) fluid samples
Mini-BAL was performed exactly as previously described. 14 Briefly, mini-BAL was performed with 16-French (Fr) double sterile catheters (KimVent BAL Cath V R , Kimberly-Clark, Roswell, GA, USA) inserted through the endotracheal tube. Two 20 mL aliquots of saline solution were instilled and then immediately aspirated with a syringe; these two BAL fluid samples were pooled and immediately centrifuged at the bedside (3000 g for 10 min at 4 C). Supernatants were stored at #80 C until analysis. For the first six patients, a mini-BAL was performed 1 and 3 h after the beginning of the first aerosolization. For the last six patients, a mini-BAL was performed 5 and 8 h after the beginning of the first aerosolization.
Colistin and CMS assay in plasma and BAL fluid A previously described LC-MS/MS assay was used for CMS and colistin concentration measurements in plasma 18 and BAL fluid 19 samples. The limit of quantification (LOQ) of colistin was 0.0097 mg/L in both media.
Urea analysis in plasma and BAL fluid
A previously described LC-MS/MS assay was used for urea concentration measurements in BAL fluid samples. 14, 20 The LOQ of the assay was 1 mg/L in BAL fluid. Urea concentrations in plasma were measured by photometric detection using an automatic analyser (Modular Automatic Analyzer, Roche, France).
Estimation of CMS and colistin concentrations in ELF
Actual ELF concentrations of CMS or colistin (C ELF ) were obtained from measured BAL fluid concentrations after correction for dilution, 19 according to the following equation:
where C BAL corresponds to the CMS or colistin concentration measured in BAL fluid, and Urea plasma and Urea BAL correspond to the concentrations of urea determined in plasma and BAL fluid, respectively.
Determination of the adsorption of CMS and colistin to inner surfaces of mini-BAL devices
An in vitro study was performed in triplicate within a range of concentrations of CMS or colistin of 0.06, 0.6 and 6 mg/L. Concentrations in saline solutions were determined before and after handling with the same double sterile catheter (KimVent BAL Cath V R , Kimberly-Clark, USA), syringes (Injekt V R , B. Braun, Germany) and vials (Cryovial V R , Simport, Canada) that were used for ELF sampling.
Pharmacokinetic analysis
Individual pharmacokinetic analysis was performed for CMS and colistin plasma concentrations by a non-compartmental method with Phoenix V R WinNonlin 6.3 (Certara L.P., St Louis, MO, USA). The following CMS and colistin pharmacokinetic parameters were derived for each subject: the plasma C max and the time taken to reach C max (T max ) were obtained directly from the concentration-time data; plasma AUC from time zero (pre-dose) to the last quantifiable concentration (AUC last ) were calculated using a linear trapezoidal method. These were expressed as median (IQR). Dose-normalized pharmacokinetic parameters were statistically compared between 0.5 and 2 MIU dosage regimens with a linear model by using R software (v 3.1.0, function lm). The systemic bioavailability of CMS following 0.5 MIU of nebulized CMS was determined with AUC 0-8 of CMS in plasma.
Results
Patients
A total of three women and nine men were enrolled. Their demographic, clinical and biological data are shown in Table 1 . Patient 4 was excluded from analysis because of an aerosol delivery defect.
Colistin adsorption to inner surfaces of mini-BAL devices
In saline solution, in vitro study showed no major adsorption of CMS to mini-BAL devices whatever the concentration. For colistin, the non-specific adsorption was not significant for concentrations equal to 6 mg/L, but at 0.6 mg/L $80% of colistin stuck nonspecifically to the mini-BAL device and at 0.06 mg/L concentrations were below the LOQ (0.0097 mg/L).
Pulmonary pharmacokinetics
CMS and colistin concentrations measured in BAL after 0.5 MIU nebulization of CMS were below the LOQ for 6 and 7 of the 22 BAL fluid assays, respectively. The median dilution factor estimated from the urea ratio was 51. Median CMS concentrations in ELF ranged from 1 to 20 mg/L between 1 and 8 h post-dose. CMS and colistin concentrations were much higher ($100-to 1000-fold) in ELF than in plasma, but still had high variability. However, as colistin concentrations measured in BAL were always ,6 mg/L, colistin ELF concentrations should be considered with caution because of non-specific adsorption to mini-BAL devices, as discussed later, and for this reason only ELF concentrations of CMS are shown in Figure 1 , together with concentrations measured after a 2 MIU dose after normalization to a 0.5 MIU dose 14 for comparison purposes. 6  41  86  2  63  male  185  95  thoracic injury  3  32  67  3  62  female  163  73  pulmonary embolism  6  27  45  5  67  male  180  97  oesophageal fistula  3  28  186  6  35  male  184  90  cerebrovascular accident  8  40  94  7  37  male  180  88  traumatic brain injury  5  38  110  8  81  female  166  76  gastrointestinal haemorrhage  4  37  160  9  71  male  180  66  post-operative pulmonary lobectomy  3  24  207  10  76  male  175  79  respiratory decompensation  7  48  88  11  53  male  169  75  cardiopulmonary arrest  15  61  170  12  56  male  170  87  oesophageal fistula  5  13 (Table 2) and not significantly different (P . 0.05), but CMS T max was shorter after 0.5 than after 2 MIU nebulization of CMS (0.53 versus 1.50 h; P , 0.05).
Discussion
A previous study has shown that after nebulization of 2 MIU of CMS in critically ill patients, colistin concentrations in ELF were very high (.100 mg/L in most of cases), whereas plasma concentrations were low (,1 mg/L).
14 Therefore, it was hypothesized that aerosol dosage of CMS could be advantageous for the treatment of pulmonary infections, but that a 2 MIU dose is probably unnecessarily high. The aim of the present study was therefore to assess the systemic and pulmonary pharmacokinetics of CMS and colistin after nebulization of CMS 0.5 MIU.
CMS and colistin concentrations in the ELF were obtained by mini-BAL, and demonstrated large inter-individual variability. The necessity of correcting measured BAL concentrations by urea to estimate ELF concentrations increases experimental uncertainty. However, BAL is achieved without visual control and samples may come from different lung segments, thus contributing also to the large observed inter-individual variability. Yet previous studies have shown this technique to be a reliable method in comparison with bronchoscopic BAL. 21 Furthermore, with its protected extremity, the catheter should be minimally contaminated by CMS deposited on the trachea and stem bronchi.
Note that the experimental conditions were similar between the previous study using a 2 MIU dose of CMS 14 and this new study conducted with 0.5 MIU. The similarities included the procedure and equipment used for BAL and also the analytical assay for CMS and colistin; these similarities allow comparison between the two studies. Dilution factors, determined with a urea method, were not statistically different between the two studies (median dilution Boisson et al.
factor 51 versus 33). The only differences were that the volume of nebulized CMS solution in 0.9% sodium chloride was 5 mL in this new study and 10 mL in the previous one, 14 and in the new study the CMS concentration was half of that in the previous study (8 versus 16 g/L). This is of possible concern because CMS is known to aggregate into micelles when its concentration is greater than a critical micelle concentration, estimated at 3.5 mM (5.7 g/L). 22 Moreover, deep lung deposition depends on droplet size, which is influenced by the physiochemical properties of the nebulized solution. 23 This difference in CMS concentration might impact the location of lung deposition.
After nebulization of the 0.5 MIU dosage, CMS and colistin concentrations were much greater (100-to 700-fold) in ELF than in plasma, confirming the previous reports of limited systemic absorption of CMS and colistin after aerosol delivery. 14, 20, [24] [25] [26] [27] Whereas concentrations of colistin in ELF .25 mg/L were expected from previous results with a dose of 2 MIU, 14 most of the measured concentrations were ,5 mg/L (17 of 22 ELF concentrations). Therefore, the colistin ELF concentration difference is apparently greater than the 4-fold difference between doses. Because colistin is known to bind to synthetic membranes in a concentration-dependent manner, 28, 29 it was possible that this phenomenon contributes to this discrepancy. This was confirmed by in vitro data showing that, at concentrations 6 mg/L in saline solution, a large fraction of colistin sticks to the mini-BAL device ($80% at 0.6 mg/L), whereas adsorption was negligible at a concentration of 6 mg/L. These results suggest that colistin concentrations measured in BAL during this study are not reliable, and therefore they are not reported. Previously reported data after nebulization with 2 MIU should be less affected by this problem; however, after nebulization about half of the colistin concentrations measured were ,6 mg/L in BAL and were therefore possibly under-estimated. 14 This non-specific binding may also explain why Imberti et al. 30 could not measure colistin in BAL fluid after intravenous CMS administration. As another consequence, colistin concentrations measured in ELF after the 0.5 MIU dose of CMS are difficult to compare with those following the 2 MIU dose.
However, colistin plasma concentrations are not affected by this non-specific adsorption on plastic tubing and can be compared between studies after being normalized to the same dose. For unexplained reasons, after dose normalization, the inter-patient variability of CMS and colistin plasma concentrations were lower after nebulization of CMS 0.5 MIU compared with 2 MIU 14 ( Figure 2 and Table 2 ). Because colistin plasma concentrations depend not only on the fraction of the CMS dose absorbed, but also on the presystemic and systemic conversion of CMS into colistin, plasma concentrations of the parent drug (CMS) should be used to investigate bioavailability. It is of note that AUC 0-8 represented $92% of the total AUC of CMS during the 2 MIU study; 14 therefore, it is considered that the extrapolated part of the AUC should also be minimal in the present study and that the ratio of AUC 0-8 should reflect satisfactorily the relative CMS bioavailability between the two dosages. Therefore, these results suggest that the CMS bioavailability should be $30% reduced at 0.5 MIU compared with 2 MIU.
Interestingly, however, because CMS does not bind significantly to synthetic membranes, ELF concentrations of CMS may be compared between studies and appear to be considerably less than proportional to the dose. In fact it can be observed in Figure 1 that even after normalization to the dose, ELF concentrations of CMS are roughly 10-fold lower after nebulization of 0.5 MIU (ranging between 1 and 100 mg/L with only one exception) than after nebulization of 2 MIU (ranging between 10 and 1000 mg/L with only two exceptions). The apparent decrease in bioavailability suggests that a lower fraction of the dose might reach the alveolar space at 0.5 MIU than at 2 MIU. A possible explanation is that CMS could be absorbed faster after nebulization of the lower dose. Consistent with this, CMS T max is shorter after nebulization of 0.5 MIU than after 2 MIU (0.5 versus 1.5 h). This can also be observed in Figure 2 , which also suggests that, following the 0.5 MIU dose, plasma CMS concentrations decay soon after the peak, whereas a smoother peak is observed following the 2 MIU dose.
In conclusion, ELF concentrations of the active moiety colistin after nebulization of 0.5 MIU of CMS were lower than what could be expected from a previous study conducted at a CMS dose of 2 MIU. Non-specific adsorption of colistin on the BAL tubing may partially explain this result and colistin ELF concentrations have not been reported for this reason. However, our data suggest that a slower absorption of CMS occurs after nebulization of 2 MIU. Therefore, until new pharmacokinetic and pharmacodynamic assessments of the treatment of VAP with nebulized CMS are performed, the 2 MIU dose should be preferred to the 0.5 MIU dose. 
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